Business Wire

FL-MITSUBISHI-POWER

23.6.2022 15:07:13 CEST | Business Wire | Press release

Share
ION Renewables Signs Exclusivity Agreement to Bring Mitsubishi Power’s Emerald Storage Solutions to Ireland

Renewable energy developer Ion Renewables, Ltd. (ION Renewables) has signed an exclusivity agreement with Mitsubishi Power Americas, Inc. (Mitsubishi Power) for four battery energy storage system (BESS) projects using Mitsubishi Power’s Emerald storage solutions totaling 185.5 megawatt (MW) / 371 megawatt-hours (MWh) in Ireland. These projects will provide Secure, Sustainable Electricity System (DS3) energy storage and system services including fast frequency and capacity response to Ireland’s National Grid, enabling the addition of more renewable energy. All four projects will be located at brownfield sites with existing electrical interconnects.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220622006036/en/

In addition to providing frequency response to the National Grid, the BESS projects will support three major energy initiative programs for Ireland and the European Union:

  • Ireland’s Climate Action Plan to reach net-zero greenhouse gas emissions no later than 2050
  • EirGrid Group’s DS3 program that addresses the challenges of integrating world-leading levels of renewable generation into the grid and targets having 70% of Ireland’s electricity come from renewables by 2030
  • REPowerEU’s draft directive, which seeks to eliminate imported gas by 2030 and diversify energy sources

“We are delighted to be working with the Mitsubishi Power team to deliver these important projects,” said John Ward, Director, ION Renewables. “These installations represent a viable and economical solution to balance the network, strongly aligning with the principles of the REPowerEU draft directive. These projects demonstrate that effective solutions for storing energy can be achieved by utilizing renewable power that would otherwise be curtailed.”

Scheduled to come online in 2024, the four BESS projects will be Mitsubishi Power’s first in Europe, bringing the total global deployment of its Emerald storage solutions to more than 2 gigawatt-hours (GWh).

Mitsubishi Power’s Emerald storage solutions for Ion Renewables include project engineering, equipment supply, and a 10-year long-term service agreement.

According to Tom Cornell, Senior Vice President, Energy Storage Solutions, Mitsubishi Power Americas, these projects emphasize the importance of BESS adoption as a viable solution with more countries striving to meet their climate action goals. “Bringing our Emerald storage solutions to Ireland and working with Ion Renewables is an exciting moment for us. The continued adoption of battery storage technologies outside of the United States and the recognition of the important role they play in enabling renewable energy generation to reach net-zero cannot be overstated. Mitsubishi Power’s Emerald storage solutions will help Ireland reach its goal of 70% generation from renewable sources while ensuring the stability of the grid with a secure power system.”

Read more about some of Mitsubishi Power’s BESS projects:

About Mitsubishi Power Americas, Inc.

Mitsubishi Power Americas, Inc. (Mitsubishi Power) headquartered in Lake Mary, Florida, employs more than 2,300 power generation, energy storage, and digital solutions experts and professionals. Our employees are focused on empowering customers to affordably and reliably combat climate change while also advancing human prosperity throughout North, Central, and South America. Mitsubishi Power’s power generation solutions include gas, steam, and aero-derivative turbines; power trains and power islands; geothermal systems; PV solar project development; environmental controls; and services. Energy storage solutions include green hydrogen, battery energy storage systems, and services. Mitsubishi Power also offers intelligent solutions that use artificial intelligence to enable autonomous operation of power plants. Mitsubishi Power is a power solutions brand of Mitsubishi Heavy Industries, Ltd. (MHI). Headquartered in Tokyo, Japan, MHI is one of the world’s leading heavy machinery manufacturers with engineering and manufacturing businesses spanning energy, infrastructure, transport, aerospace, and defense. For more information, visit the Mitsubishi Power Americas website and follow us on LinkedIn .

About Ion Renewables, Ltd.

Ion Renewables, Ltd. (ION Renewables) was formed by top experts in the energy storage industry with the goal of deploying energy storage to provide grid balancing and renewables integration. We are developing and advising on projects in Ireland and worldwide through our network. In this current batch of projects in Ireland, ION Renewables is developing ESS facilities at large industrial load centres, providing rapid deployment and low environmental footprint on existing brownfield sites. These projects will assist in balancing the network by providing additional functionality to the grid to enable the further deployment of renewables and ultimately reduce Ireland's dependency on imported fossil fuels. For more information, visit the ION Renewables website .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release

In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release

IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye